INHIBITION OF P53 DNA-BINDING BY HUMAN PAPILLOMAVIRUS E6 PROTEINS

被引:179
作者
LECHNER, MS
LAIMINS, LA
机构
[1] NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,CHICAGO,IL 60611
[2] UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637
[3] UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637
关键词
D O I
10.1128/JVI.68.7.4262-4273.1994
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Transformation by the human papillomavirus (HPV) early gene products, E6 and E7, involves their interaction with cellular proteins p53 and Rb. Using glutathione S-transferase (GST) fusion proteins, we found that HPV E6 bound human p53 and that the relative efficiency of binding varied such that the GST-HPV type 16 E6 (16E6) protein bound p53 with highest affinity, followed by GST-31E6, GST-18E6, and GST-11E6. The GST-E6 fusion proteins were sufficient for binding p53 purified from a baculovirus expression system as well as in vitro translation sources, while no association was observed with GST-18E7 or a GST-16E6 mutant bearing a five-amino-acid deletion in E6. When the site-specific DNA binding activity of p53 was examined in the presence of GST-E6 proteins, an inhibition of DNA binding was observed. The degree of inhibition correlated with the relative affinity of different E6 proteins for p53; thus, GST-16E6 was the most potent inhibitor of p53 DNA binding activity, and GST-11E6 was the least effective. Prevention of p53 DNA binding is likely to play a role in the abrogation of the transcriptional activity of p53 by HPV E6 and provides a further mechanism for E6 disruption of p53 growth suppressor function in addition to its role in directing specific degradation of p53 through the ubiquitin-mediated pathway. The variation in inhibition of DNA binding seen with the various E6 proteins may thus contribute to the differences in oncogenic potential seen among the HPV types.
引用
收藏
页码:4262 / 4273
页数:12
相关论文
共 73 条
[11]   WILD-TYPE BUT NOT MUTANT P53 IMMUNOPURIFIED PROTEINS BIND TO SEQUENCES ADJACENT TO THE SV40 ORIGIN OF REPLICATION [J].
BARGONETTI, J ;
FRIEDMAN, PN ;
KERN, SE ;
VOGELSTEIN, B ;
PRIVES, C .
CELL, 1991, 65 (06) :1083-1091
[12]   PURIFICATION OF COMPLEXES OF NUCLEAR ONCOGENE-P53 WITH RAT AND ESCHERICHIA-COLI HEAT-SHOCK PROTEINS - INVITRO DISSOCIATION OF HSC70 AND DNAK FROM MURINE-P53 BY ATP [J].
CLARKE, CF ;
CHENG, K ;
FREY, AB ;
STEIN, R ;
HINDS, PW ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (03) :1206-1215
[13]   DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION [J].
CROOK, T ;
TIDY, JA ;
VOUSDEN, KH .
CELL, 1991, 67 (03) :547-556
[14]  
CROOK T, 1991, ONCOGENE, V6, P873
[15]   SV40 LARGE TUMOR-ANTIGEN FORMS A SPECIFIC COMPLEX WITH THE PRODUCT OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE [J].
DECAPRIO, JA ;
LUDLOW, JW ;
FIGGE, J ;
SHEW, JY ;
HUANG, CM ;
LEE, WH ;
MARSILIO, E ;
PAUCHA, E ;
LIVINGSTON, DM .
CELL, 1988, 54 (02) :275-283
[16]   THE HUMAN PAPILLOMA VIRUS-16 E7-ONCOPROTEIN IS ABLE TO BIND TO THE RETINOBLASTOMA GENE-PRODUCT [J].
DYSON, N ;
HOWLEY, PM ;
MUNGER, K ;
HARLOW, E .
SCIENCE, 1989, 243 (4893) :934-937
[17]   DEFINITION OF A CONSENSUS BINDING-SITE FOR P53 [J].
ELDEIRY, WS ;
KERN, SE ;
PIETENPOL, JA ;
KINZLER, KW ;
VOGELSTEIN, B .
NATURE GENETICS, 1992, 1 (01) :45-49
[18]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[19]   WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO [J].
FARMER, G ;
BARGONETTI, J ;
ZHU, H ;
FRIEDMAN, P ;
PRYWES, R ;
PRIVES, C .
NATURE, 1992, 358 (6381) :83-86
[20]   WILD-TYPE P53 CAN DOWN-MODULATE THE ACTIVITY OF VARIOUS PROMOTERS [J].
GINSBERG, D ;
MECHTA, F ;
YANIV, M ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :9979-9983